ENX-102
Phase 2Small molecule
ENX-102 is one of 12 small molecule programs targeting Social Anxiety Disorder. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Social Anxiety Disorder
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsApproved
Vraylar
AbbVieApproved
Lexapro
AbbVieApproved
Zoloft
VViatris Specialty LLC
Approved
Paxil
SSebela Pharmaceuticals Development LLC
Approved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Klonopin
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Effexor
WWyeth-Lederle Vaccines
Approved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Transderm Scop
BBaxter Healthcare Corporation
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Social Anxiety Disorder1 trial
Generalized Anxiety Disorder1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ENX-102. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EEngrail Therapeutics INC